Can machine learning unravel unsuspected, clinically important factors predictive of long-term mortality in complex coronary artery disease? A call for ‘big data’ — Kai Ninomiya (2023) | RDL Network
Can machine learning unravel unsuspected, clinically important factors predictive of long-term mortality in complex coronary artery disease? A call for ‘big data’
European Heart Journal - Digital Health 4(3): 275-278
Article 2023 English
Authors
KN
Kai Ninomiya
SK
Shigetaka Kageyama
SG
Scot Garg
Abstract
1 min read
Aims Risk stratification and individual risk prediction play a key role in making treatment decisions in patients with complex coronary artery disease (CAD). The aim of this study was to assess whether machine learning (ML) algorithms can improve discriminative ability and identify unsuspected, but potentially important, factors in the prediction of long-term mortality following percutaneous coronary intervention or coronary artery bypass grafting in patients with complex CAD. Methods and results To predict long-term mortality, the ML algorisms were applied to the SYNTAXES database with 75 pre-procedural variables including demographic and clinical factors, blood sampling, imaging, and patient-reported outcomes. The discriminative ability and feature importance of the ML model was assessed in the derivation cohort of the SYNTAXES trial using a 10-fold cross-validation approach. The ML model showed an acceptable discrimination (area under the curve = 0.76) in cross-validation. C-reactive protein, patient-reported pre-procedural mental status, gamma-glutamyl transferase, and HbA1c were identified as important variables predicting 10-year mortality. Conclusion The ML algorithms disclosed unsuspected, but potentially important prognostic factors of very long-term mortality among patients with CAD. A ‘mega-analysis’ based on large randomized or non-randomized data, the so-called ‘big data’, may be warranted to confirm these findings. Clinical Trial Registration SYNTAXES ClinicalTrials.gov reference: NCT03417050, SYNTAX ClinicalTrials.gov reference: NCT00114972
Masafumi Ono, Hideyuki Kawashima, Hironori Hara, Massimo Mancone, Michael J. Mack, David R. Holmes, Marie‐Claude Morice, A. Pieter Kappetein, Daniel J.F.M. Thuijs, Thilo Noack, Friedrich W. Mohr, Piroze Davierwala, Yoshinobu Onuma, Patrick W. Serruys
Kai Ninomiya, Shigetaka Kageyama, Hiroki Shiomi, Nozomi Kotoku, Shinichiro Masuda, Pruthvi C. Revaiah, Scot Garg, Neil O’Leary, David van Klaveren, Takeshi Kimura, Yoshinobu Onuma, Patrick W. Serruys
Kai Ninomiya, Patrick W. Serruys, Shigetaka Kageyama, Nozomi Kotoku, Shinichiro Masuda, Pruthvi Chenniganahosahalli Revaiah, Neil O’Leary, A. Pieter Kappetein, David R. Holmes, Yoshinobu Onuma
Shigetaka Kageyama, Patrick W. Serruys, Kai Ninomiya, Antonio Colombo, R J Van Genus, Milanko Milojević, Michael J. Mack, Alan Soo, Yoshinobu Onuma, Piroze Davierwala
Discussion(0)
No comments yet. Be the first to comment.